Personalis Secures Medicare Coverage for NeXT Personal Lung Cancer MRD Test for Stage I–III Patients
Personalis’s NeXT Personal molecular residual disease test for Stage I–III non-small cell lung cancer received national Medicare coverage, enabling reimbursement for genomic surveillance of up to 1,800 mutations. The decision follows TRACERx validation and is expected to broaden patient access and serve as a key growth driver for the company.
1. Medicare Coverage Approval
Personalis secured national Medicare coverage for its NeXT Personal molecular residual disease test, which will now be reimbursed for patients with Stage I–III non-small cell lung cancer under Medicare Part B. This approval removes a key barrier to adoption by reducing out-of-pocket costs for eligible beneficiaries.
2. Advanced Test Technology
NeXT Personal leverages ultra-deep genomic sequencing to track up to 1,800 tumor mutations, offering high sensitivity for detecting molecular residual disease. Clinical validation from the TRACERx collaboration demonstrated the assay’s accuracy in identifying recurrence and monitoring residual cancer cells.
3. Market Impact and Outlook
The coverage decision is positioned as a growth catalyst, with CEO Chris Hall projecting expanded market penetration and revenue acceleration in the oncology segment. Shares have risen over 56% in the past 12 months and carry a consensus Buy rating with an average price target of $11.78.